Every Teladoc Investor Should Keep an Eye on This Number
Hint: You won't find it on the top or bottom lines.
Teladoc Health, Inc. (TDOC) Q3 2024 Earnings Call Transcript
Teladoc Health, Inc. (NYSE:TDOC ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Michael Minchak - Head of Investor Relations Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Stephanie Davis - Barclays Lisa Gill - JPMorgan Jessica Tassan - Piper Sandler Michael Cherny - Leerink Partners Sean Dodge - RBC Capital Markets Sarah James - Cantor Fitzgerald Jailendra Singh - Truist Securities Richard Close - Cannacord Glen Santangelo - Jefferies Charles Rhyee - TD Cowen Allen Lutz - Bank of America Sameer Patel - Evercore ISI Operator Hello, and welcome to the Teladoc Health Third Quarter 2024 Call. My name is Alex, and I'll be coordinating the call today.
Teladoc (TDOC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc (TDOC) Reports Q3 Loss, Tops Revenue Estimates
Teladoc (TDOC) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago.
Exploring Analyst Estimates for Teladoc (TDOC) Q3 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Teladoc (TDOC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Teladoc (TDOC) Stock Dips While Market Gains: Key Facts
The latest trading day saw Teladoc (TDOC) settling at $8.60, representing a -0.92% change from its previous close.
Teladoc Health Needs A Turnaround Plan
Teladoc Health, Inc. shows signs of bottoming out after withdrawing guidance due to customer acquisition issues, particularly in the BetterHelp division. The new CEO must drive product innovation to capitalize on growth opportunities in weight loss management and chronic care management. The stock is trading at a deep valuation, around 5x EBITDA targets, providing a potential investment opportunity despite current challenges.
Teladoc (TDOC) Stock Sinks As Market Gains: Here's Why
Teladoc (TDOC) reachead $8.41 at the closing of the latest trading day, reflecting a -0.71% change compared to its last close.
Why Teladoc Stock Popped by Nearly 12% on Tuesday
An analyst raised his price target on the telehealth leader. The 25% increase was considerable.
Teladoc rises on increased demand, should you buy this high risk play?
Teladoc health's services witness an increase in demand according to the latest web traffic figures, as per Jeffries analysts.
Why Teladoc (TDOC) Outpaced the Stock Market Today
Teladoc (TDOC) closed at $8.16 in the latest trading session, marking a +0.87% move from the prior day.
